


ALLERGAN: THE GLOBAL LEADER IN BREAST AESTHETICS¹

OVER 40 YEARS
OF EXPERIENCE^{2,3*}

Breast implants available



in **100+** countries⁴




16,000+
employees
worldwide in 2016⁵



\$1.5 billion USD
invested in global research &
development in 2016 across
all therapeutic areas⁵

NATRELLE[®]: A LEGACY OF MANUFACTURING EXCELLENCE⁶⁻⁸



Manufactured in a state-of-the-art manufacturing facility in Costa Rica⁹
• **600+** highly skilled, certified employees¹⁰

Extensive implant manufacturing process
that can take up to **12 days**⁷



Each breast implant undergoes **93** quality control checks
and meets globally recognized quality standard approvals⁶

Breast implants and tissue expanders are
FDA approved⁸



900,000+
implants and tissue expanders
manufactured annually¹¹



Over **3.7 million**
implants & expanders
distributed worldwide¹²

*McGhan began marketing breast implants in 1974 and was acquired by First American in 1985, whose name was later changed to Inamed. In 2006, Allergan acquired Inamed.^{2,3}

COMMITTED TO PRODUCING WELL-RESEARCHED, QUALITY PRODUCTS^{5,13}



25 mid-to-late stage research & development programs
in aesthetics and dermatology⁵

Most published implant manufacturer in the last 2 years based on a literature search comparing Allergan, Mentor[®] and Sientra^{®13}

- Allergan sponsored trials investigated a number of different breast implant products¹⁴
- Allergan has breast implant trials outside the United States¹⁵



CONTINUOUS ADVANCEMENT OF OUR BREAST IMPLANTS THROUGH ONGOING RESEARCH



3 long-term follow-up studies assessed safety and efficacy of breast implants in clinical practice¹⁶⁻¹⁸



Over **500,000** person-years of long-term prospective multicenter studies with Natrelle[®] implants¹⁹



Tissue interaction of Natrelle[®] implants have been researched and **tested across the entire biocompatibility matrix** of gel, shape and surface options available²⁰


THE MOST COMPREHENSIVE BREAST AESTHETICS PORTFOLIO TO ADDRESS YOUR PATIENTS' INDIVIDUAL NEEDS²¹



Implants²¹



Tissue expanders²¹



Acellular dermal matrices²¹



Fat grafting²¹



Delivery assistance sleeve²¹

Natrelle
your TruForm[™]

Natrelle
133plus
tissue expander

AlloDerm[™]

ARTIA[™]

Strattice[™]

REVOLVE[™]
Advanced Adipose System

Keller
Funnel²

LifeCell[™] Corporation, a part of Allergan Group.

Keller Medical is an affiliate of Allergan plc.

ALLERGAN, YOUR #1 MEDICAL AESTHETICS COMPANY!²²

References: **1.** Allergan Inc. Data on File: Global Aesthetics Market Study - Breast Implant Global Shares, INT/0931/2017. **2.** Bondurant S, Ernerst V, Herdman R. Safety of silicone breast implants: report of the committee on the safety of silicone breast implants (IOM). Washington, DC: National Academy Press; 1999. **3.** Allergan Inc. Data on File: Global Breast Implants Market 2014-2018, INT/0254/2017. **4.** Allergan Inc. Data on File: Implant availability worldwide, INT/0249/2017. **5.** Allergan Inc. Allergan Fact Sheet: This is Allergan. [cited 2017 Jan 20]. Available from: https://allergan-web-cdn-prod.azureedge.net/actavis/actavis/media/allergan-pdf-documents/investors/corporate%20fact%20sheet/allergan-fact-sheet_this-is-allergan_080416.pdf. **6.** Allergan Inc. Data on File: Number of Quality Control Checks in 2016 (Breast Implant Manufacturing), INT/0157/2017. **7.** Allergan Inc. Data on File: Allergan Breast Implants Manufacturing Process, INT/0253/2017. **8.** Allergan Inc. Data on File: Natrelle Quality Standard Approvals, INT/0654/2017. **9.** Allergan Inc. Data on File: Natrelle[®] manufacturing information, INT/0353/2017. **10.** Allergan Inc. Data on File: Number of Employees at Costa Rica Manufacturing Facility, INT/0158/2017. **11.** Allergan Inc. Data on File: Number of Implants & Expanders Manufactured in 2016, INT/0156/2017. **12.** Allergan Inc. Data on File: Worldwide Distribution of Implants & Expanders to Date (Dec 31, 2016), INT/0073/2017. **13.** Allergan Inc. Data on File: Data on Most Published Implant Manufacturer 2014-2016, INT/0246/2017. **14.** Allergan Inc. Data on File: Allergan Breast Implant Analysis, INT/0247/2017. **15.** Allergan Inc. Data on File: Allergan Breast Implant Analysis Published Journal Articles 2016, INT/0256/2017. **16.** Maxwell GP, Van Natta BW, Bengtson BP, Murphy DK. Ten-year results from the Natrelle 410 anatomical form-stable silicone breast implant core study. *Aesthet Surg J.* 2015;35(2):145-55. **17.** McGuire P, Reisman NR, Zins J, Murphy DK. Risk Factor analysis for capsular contracture, malposition, and late seroma in subjects receiving natrelle style 410 form-stable silicone breast implants. *Plast Reconstr Surg.* 2009;33(3):430-6. **18.** Hedén P, Bronz G, Elberg JJ, Deraemaeker R, Murphy DK, Slicton A, et al. Long-term safety and effectiveness of style 410 highly cohesive silicone breast implants. *Aesthet Plast Surg.* 2009;33(3):430-6. **19.** Allergan Inc. Data on File: Person-Years of Follow-up in Long-Term Prospective Breast Clinical Studies, INT/0154/2017. **20.** Allergan Inc. Data on File: BR-0001 Biocompatibility Review of Gel-filled Mammary Implants, INT/0261/2017. **21.** Allergan Inc. Data on File: Most Comprehensive Breast Portfolio, INT/0626/2017. **22.** Allergan Inc. Data on File: Global Aesthetic Market Study, INT/0683/2017.



Please populate trademark statements locally.

INT/0836/2017 Date of preparation: Nov 2017

Natrelle
your TruForm[™]